Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Hayley S. Ma"'
Autor:
Elizabeth M. Jaffee, Todd Armstrong, Valerie Z. Wall, Skylar Woolman, Kayla Cruz, Blake Scott, Brian Christmas, Tara M. Robinson, John-William Sidhom, Evanthia Roussos Torres, Bibhav Poudel, Hayley S. Ma
In cancers with tumor-infiltrating lymphocytes (TILs), monoclonal antibodies (mAbs) that block immune checkpoints such as CTLA-4 and PD-1/PD-L1 promote antitumor T-cell immunity. Unfortunately, most cancers fail to respond to single-agent immunothera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6a617d0ba2f7990a4e08436eb0a6826
https://doi.org/10.1158/2326-6066.c.6549304.v1
https://doi.org/10.1158/2326-6066.c.6549304.v1
Autor:
Evanthia T. Roussos Torres, Elizabeth M. Jaffee, Nilo A. Azad, Roisin M. Connolly, Todd D. Armstrong, Skylar Woolman, Kayla A. Cruz, Hayley S. Ma, Blake A. Scott, Alexander C. Hopkins, Christine I. Rafie, Brian J. Christmas
The supplemental tables include: antibodies used for flow cytometry; gene expression of genes involved in innate and adaptive immunity from whole tumors isolated from neu-N mice.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7bd3a23d62a3fdb27f3502630a400bf
https://doi.org/10.1158/2326-6066.22538896
https://doi.org/10.1158/2326-6066.22538896
Autor:
Elizabeth M. Jaffee, Todd Armstrong, Valerie Z. Wall, Skylar Woolman, Kayla Cruz, Blake Scott, Brian Christmas, Tara M. Robinson, John-William Sidhom, Evanthia Roussos Torres, Bibhav Poudel, Hayley S. Ma
Supplementary Table S1, Supplementary Figures S1-7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac3366e8dae0103ee213e1f48bdee0eb
https://doi.org/10.1158/2326-6066.22540174
https://doi.org/10.1158/2326-6066.22540174
Autor:
Evanthia T. Roussos Torres, Elizabeth M. Jaffee, Nilo A. Azad, Roisin M. Connolly, Todd D. Armstrong, Skylar Woolman, Kayla A. Cruz, Hayley S. Ma, Blake A. Scott, Alexander C. Hopkins, Christine I. Rafie, Brian J. Christmas
This file contains supplemental figures that includes: FACS gating strategies; QC plots for NanoString cell typing; survival and tumor growth of neu-N mice receiving ENT and ICIs without �-HER2; circulating MDSCs and absolute numbers of G-MDSCs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c5561698696205b6427f8b02775c68e
https://doi.org/10.1158/2326-6066.22538899.v1
https://doi.org/10.1158/2326-6066.22538899.v1
Autor:
Evanthia T. Roussos Torres, Elizabeth M. Jaffee, Nilo A. Azad, Roisin M. Connolly, Todd D. Armstrong, Skylar Woolman, Kayla A. Cruz, Hayley S. Ma, Blake A. Scott, Alexander C. Hopkins, Christine I. Rafie, Brian J. Christmas
Immune-checkpoint inhibition (ICI) has revolutionized treatment in cancers that are naturally immunogenic by enabling infiltration of T cells into the tumor microenvironment (TME) and promoting cytotoxic signaling pathways. Tumors possessing complex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e252e85b4ea5bba5580656a736573b9
https://doi.org/10.1158/2326-6066.c.6548935.v1
https://doi.org/10.1158/2326-6066.c.6548935.v1
Autor:
Evanthia T. Roussos Torres, Elizabeth M. Jaffee, Nilo A. Azad, Roisin M. Connolly, Todd D. Armstrong, Skylar Woolman, Kayla A. Cruz, Hayley S. Ma, Blake A. Scott, Alexander C. Hopkins, Christine I. Rafie, Brian J. Christmas
Supplementary figure legends (S1-S11) clean AND supplementary table legends (1-2) clean.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86a1ecb99bc3175db58fdb19be563c9c
https://doi.org/10.1158/2326-6066.22538902.v1
https://doi.org/10.1158/2326-6066.22538902.v1
Autor:
Donald Small, Christine A. Pratilas, Keith W. Pratz, Mark J. Levis, Richard J. Jones, Michelle A. Rudek, Alice Can Ran Qin, Li Li, Hayley S. Ma, J. Kyle Bruner
Figure S1: Sorafenib treatment induces phospho-ERK rebound in 32D/ITD cells. Figure S2: Further characterization of FLT3 inhibitor-mediated signaling adaptation. Figure S3: FLT3 signaling is maintained in low serum conditions. Figure S4: MEK inhibito
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fab0992900dd1d02e43c4ebf8f2c310
https://doi.org/10.1158/0008-5472.22414571
https://doi.org/10.1158/0008-5472.22414571
Autor:
Donald Small, Christine A. Pratilas, Keith W. Pratz, Mark J. Levis, Richard J. Jones, Michelle A. Rudek, Alice Can Ran Qin, Li Li, Hayley S. Ma, J. Kyle Bruner
FMS-like tyrosine kinase-3 (FLT3) tyrosine kinase inhibitors (TKI) have been tested extensively to limited benefit in acute myeloid leukemia (AML). We hypothesized that FLT3/internal tandem duplication (ITD) leukemia cells exhibit mechanisms of intri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::498ec01b8b7cb5fbbc354902e39bf311
https://doi.org/10.1158/0008-5472.c.6509027.v1
https://doi.org/10.1158/0008-5472.c.6509027.v1
Autor:
Donald Small, Christine A. Pratilas, Keith W. Pratz, Mark J. Levis, Richard J. Jones, Michelle A. Rudek, Alice Can Ran Qin, Li Li, Hayley S. Ma, J. Kyle Bruner
Table S1: AML Patient Characteristics Table S2: Plasma sample characteristics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23681dc443118c6a306f8231da28ee2f
https://doi.org/10.1158/0008-5472.22414568.v1
https://doi.org/10.1158/0008-5472.22414568.v1
Autor:
Donald Small, Daniel J. Leahy, Mark J. Levis, Patrick A. Brown, Allen B. Williams, Allison Galanis, Li Li, Amy S. Duffield, Bao Nguyen, Hayley S. Ma
Supplemental Table 1. Proliferation IC50 for treatment of FLT3 activating mutant cells. Supplemental Table 2. FLT3 mutational status and proliferation IC50 of AML patient samples. Supplemental Table 3. Phospho-FLT3 IC50 in plasma culture conditions.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a58faee672d4b25f5cb165ef233727f1
https://doi.org/10.1158/0008-5472.22403495.v1
https://doi.org/10.1158/0008-5472.22403495.v1